Full analysis of Pemigatinib drug production company and manufacturer information

Pemigatinib is a FGFR-targeted anti-tumor drug developed and launched by Incyte Corporation, an American innovative pharmaceutical company. As the world's first approved drug for FGFR2 fusion or rearrangement of cholangiocarcinoma, the R&D, production and commercialization of pemetinib are mainly led by Incyte . It has a complete international market layout and is the core original research company of this drug. Incyte Headquartered in Delaware, USA, it is famous for its focus on developing targeted drugs for rare cancers and unmet clinical needs. Pemetinib is one of its representative products.

Globally, the original research production, quality standard setting and formulation release of pemetinib are all completed by Incyte . The company is responsible for the filing, production and listing of products in major regulatory markets such as the United States, Europe and Japan. As an original drug, the production of finished products of pemetinib mostly adopts the global contract manufacturing organization (CMO) system certified by Incyte to ensure drug quality and supply stability. In addition, the drug is directly responsible for sales and medical support internationally by Incyte , making it an important choice for FGFR targeted treatment of cholangiocarcinoma in many countries.

In the Chinese market, the development and commercialization of pemetinib is licensed by Incyte to Innovent Biologics (Innovent Biologics). Innovent Biologics is an innovative pharmaceutical company with complete R&D, production and sales systems in China. It is responsible for the clinical trials, registration application and marketing promotion of pemetinib in mainland China, Hong Kong and Macau. According to the cooperation agreement between the two parties, Innovent Biologics is responsible for the localized production and sales of pemetinib in China, allowing the drug to be approved and used faster in Greater China.

To summarize, the global production system of pemetinib is dominated by the original research company Incyte , and Innovent Biologics is responsible for local development and listing in the Chinese market. The two constitute its most important production and commercialization entities. As a targeted drug specifically targeting FGFR2 fusion cholangiocarcinoma, pemetinib has formed a mature original research quality system and regional licensing model in the world. Its production, research and development and supply chain structure are relatively stable, and it is currently one of the most comprehensive drugs in the field of targeted treatment of cholangiocarcinoma.

Keyword tag:

Pemetinib, production company, Incyte, Innovent Biologics, manufacturer information, original drug, generic drug, global market, Chinese market

Reference materials:https://www.oncologynewscentral.com/drugs/monograph/179187-320027/pemigatinib-oral